Loading…
Loading…
LUNG does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for LUNG and 80,000+ other tickers.
See exactly how LUNG's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for LUNG and 80,000+ other tickers.
Pulmonx Corporation is a biomedical technology firm dedicated to developing and commercializing advanced, less invasive devices for managing chronic obstructive pulmonary diseases. Its primary offering, the Zephyr Endobronchial Valve, is specifically engineered to treat bronchoscopic hyperinflation in adults afflicted with severe emphysema. Complementing its therapeutic solutions, the company also provides the Chartis Pulmonary Assessment System. This system features a specialized balloon catheter and console, fitted with flow and pressure sensors, which is instrumental in evaluating the…
After reaching an important support level, Pulmonx Corporation (LUNG) could be a good stock pick from a technical perspective. LUNG recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.
Pulmonx NASDAQ: LUNG is rebuilding its sales organization, targeting a return to growth and preparing for potential commercialization of its AeriSeal therapy outside the United States in the second half of next year, President and CEO Glen French said during a Canaccord fireside chat.
Does Pulmonx Corporation (LUNG) have what it takes to be a top stock pick for momentum investors? Let's find out.
Pulmonx (LUNG) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Pulmonx Corporation (LUNG) Q2 2026 Earnings Call Transcript